Awareness of a patient’s potential procedures and changes in nutritional intake enables the pharmacist to prevent hypoglycemic events by proactively adjusting the insulin regimen.
The updated formulations more closely target the XBB lineage of the Omicron variant, and it is anticipated that they will better fight currently circulating variants.
This agent recently achieved an additional indication to reduce myocardial infarction, stroke, coronary revascularization, and cardiovascular death risk in adult patients with ASCVD.